ARCA biopharma, Inc. (ABIO)
- Previous Close
3.4800 - Open
3.6800 - Bid 3.5500 x 200
- Ask 3.5900 x 200
- Day's Range
3.5001 - 3.6800 - 52 Week Range
1.5600 - 3.8800 - Volume
85,291 - Avg. Volume
1,422,461 - Market Cap (intraday)
51.914M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date Jul 19, 2024 - Jul 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
www.arcabio.comRecent News: ABIO
Performance Overview: ABIO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABIO
Valuation Measures
Market Cap
51.91M
Enterprise Value
14.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.42%
Return on Equity (ttm)
-15.87%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
35.9M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.61M
Research Analysis: ABIO
Company Insights: ABIO
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ABIO
Daily – Vickers Top Buyers & Sellers for 05/27/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/18/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/13/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/08/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.